Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around...
February 21, 2025 08:30 ET | Source: Stemline Therapeutics, Inc.

Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help...
January 10, 2025 09:00 ET | Source: Stemline Therapeutics, Inc.

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
August 01, 2023 09:30 ET | Source: Mordor Intelligence

Aesthetic Threads Market Revenues to Reach USD 204.14 billion by 2028 - Market Size, Share, Forecasts, & Trends Analysis Report by Mordor Intelligence

Hyderabad, Aug. 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled "Aesthetic Threads Market Report (2023-2028)," the market is estimated at USD 142.99 billion in 2023. It...
May 19, 2020 12:23 ET | Source: Bragar Eagel & Squire

STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
December 21, 2018 08:00 ET | Source: Helsinn Healthcare S.A.

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat

Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...
March 02, 2017 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Menarini Group Enter into Commercial and Co-Development Agreement for Delafloxacin in 68 Countries

NEW HAVEN, Conn. and FLORENCE, Italy, March 02, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, and...